Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Zealand Pharma A/S ADR (ZEAL)

Zealand Pharma A/S ADR (ZEAL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 986,420
  • Shares Outstanding, K 31,820
  • Annual Sales, $ 6,020 K
  • Annual Income, $ 92,080 K
  • 60-Month Beta 2.06
  • Price/Sales 172.42
  • Price/Cash Flow 10.81
  • Price/Book 4.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.28
  • Number of Estimates 2
  • High Estimate 0.14
  • Low Estimate -0.70
  • Prior Year -0.61
  • Growth Rate Est. (year over year) +54.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.70 +4.92%
on 11/22/19
36.84 -15.42%
on 11/18/19
-0.28 (-0.90%)
since 11/12/19
3-Month
23.00 +35.48%
on 10/11/19
36.84 -15.42%
on 11/18/19
+7.33 (+30.76%)
since 09/12/19
52-Week
11.56 +169.55%
on 12/26/18
36.84 -15.42%
on 11/18/19
+17.98 (+136.42%)
since 12/12/18

Most Recent Stories

More News
Zealand Initiates Second Late-Stage CHI Study on Dasiglucagon

Zealand (ZEAL) announces initiation of the second phase III study to evaluate dasiglucagon in pediatric patients with congenital hyperinsulinism.

ANIK : 53.50 (-1.38%)
ALKS : 21.25 (+1.53%)
BDSI : 6.46 (+1.57%)
ZEAL : 31.16 (+0.52%)
Bernadette Connaughton Appointed to Syneos Health Board of Directors

Syneos Health (Nasdaq:SYNH), a leading biopharmaceutical solutions organization combining a Contract Research Organization (CRO) and a Contract Commercial Organization (CCO), today announced the appointment...

ZEAL : 31.16 (+0.52%)
HALO : 18.72 (-0.11%)
SYNH : 57.36 (+2.23%)
Will Zealand Pharma Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Zealand Pharma.

ZEAL : 31.16 (+0.52%)
Oncolytics Biotech(R) Appoints Experienced Financial and Strategic Leader Leonard Kruimer to Board of Directors

SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / October 17, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, is...

JNJ : 141.34 (+0.26%)
ONCY : 1.11 (-0.89%)
ONC.TO : 1.44 (-2.70%)
ZEAL : 31.16 (+0.52%)
MDCO : 84.03 (-0.05%)
Biotech Stock Roundup: Pipeline Updates From REGN, BIIB, AMGN and More

Key highlights of the past week include regulatory and pipeline updates, licensing deals, and more.

CLVS : 13.43 (+14.59%)
BIIB : 293.85 (+0.55%)
AMGN : 235.99 (+0.85%)
REGN : 372.16 (-0.37%)
ZEAL : 31.16 (+0.52%)
Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes

Boehringer Ingelheim and Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL), have announced that Boehringer Ingelheim plans to initiate Phase 2 development of the GLP-1/glucagon dual agonist BI 456906, which...

ZEAL : 31.16 (+0.52%)
Report: Developing Opportunities within Apergy, vTv Therapeutics, Arcimoto, Lipocine, Zealand Pharma A/S, and AquaBounty Technologies -- Future Expectations, Projections Moving into 2019

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Apergy Corporation (NYSE:APY), vTv...

APY : 29.11 (+4.08%)
VTVT : 1.51 (unch)
FUV : 1.66 (+7.79%)
LPCN : 0.35 (-4.89%)
ZEAL : 31.16 (+0.52%)
AQB : 2.02 (-3.81%)
Alexion and Zealand Pharma Announce Collaboration to Discover and Develop Peptide Therapies for Complement-Mediated Diseases

--- Agreement provides Alexion with exclusive worldwide licenses for one preclinical target, with option for up to three additional targets, in the complement pathway -

ALXN : 112.47 (+2.71%)
ZEAL : 31.16 (+0.52%)
Zealand Pharma announces full-year 2018 results, strong cash position to support pipeline progress

Company announcement - No. 03 / 2019

ZEAL : 31.16 (+0.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ZEAL with:

Business Summary

Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. Zealand Pharma A/S is based in Copenhagen, Denmark.

See More

Key Turning Points

2nd Resistance Point 32.00
1st Resistance Point 31.58
Last Price 31.16
1st Support Level 30.95
2nd Support Level 30.74

See More

52-Week High 36.84
Last Price 31.16
Fibonacci 61.8% 27.18
Fibonacci 50% 24.20
Fibonacci 38.2% 21.22
52-Week Low 11.56

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar